Last reviewed · How we verify
NCT04220970
Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
trial testing BIA-ALCL in Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) in 150 participants. Currently enrolling.
7 June 2032
Quick facts
| Lead sponsor | The Lymphoma Academic Research Organisation |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 7 June 2017 |
| Primary completion | 7 June 2032 |
| Estimated completion | 7 June 2032 |
| Sites | 31 locations across Belgium, France |
Drugs / interventions tested
- BIA-ALCL
Conditions studied
- Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) — all drugs for Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) →
Sponsor
The Lymphoma Academic Research Organisation — full company profile →
Who can join
18 and older, female only, with Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant. Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a BIA-ALCL case registry, in connection with a national Multidisciplinary meeting (Réunion de Concertation Pluridisciplinaire nationale de recours- RCP). This registry is opened in France and in Belgium
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04220970
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Lymphoma Academic Research Organisation trials
Trials by the same sponsor.
- NCT06994169 — Glofitamab in Real Life · recruiting
- NCT06592846 — FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up · completed
- NCT06271057 — Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse · Phase 2 · recruiting
- NCT05529524 — Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) · completed
- NCT04802590 — Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04220970 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Lymphoma Academic Research Organisation
- Last refreshed: 14 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04220970.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing